Vascular Endothelial Growth Factor Services
-
based in FRANCE
Age-related macular degeneration is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America and Europe. The global impact is significant with current projected estimates for people living with AMD of around 200 million people worldwide and expected rapid growth due to aging ...
-
Manufactured by Salutaris Medical Devices, Inc. (SMD)based in USA
Anti-VEGF Resistant Disease; 20+ million seniors suffer vision loss from wet-AMD (advanced age-related macular degeneration). The current treatment for wet-AMD is frequent (sometimes monthly) injections of anti-VEGF directly into the ...
-
Manufactured by Alfa Chemistrybased in USA
Tamoxifen citrate is an estrogen receptor antagonist and partial agonist which has been shown to induce apoptosis in human malignant glioma cells and to block VEGF production in breast cancer cells. Alfa Chemistry offers high quality tamoxifen citrate to customers which meets the CP & USP standards. Please feel free to contact us for APIs or technical services. Learn more at ...
-
Manufactured by Biomatik Corporationbased in CANADA
Biomatik has been proudly serving 10,000+ scientists since 2002. Biomatik is proud to offer high quality and speedy peptide synthesis service at the most affordable prices in the industry: as low as $3/aa or $90/peptide, and as fast as 2-3 weeks for most peptides under 30aa! Our extensive experience in peptide synthesis technologies has afforded us the capability to take on a wide range of ...
-
Manufactured by Ellex Inc.based in USA
Despite the evolving role of anti-VEGF medications in the treatment of retinal disease, laser photocoagulation remains a mainstream treatment pathway for patients with diabetic retinopathy, enabling ophthalmologists around the world to alleviate the causes and symptoms of vision loss associated with the ...
-
based in USA
Aptamer discovery is a complex process. Customized libraries and selection techniques are employed to achieve selective binding to a target of interest under anticipated conditions. In some cases, selected aptamers may not quite achieve the degree of affinity or stability required for a specific end-use application. In addition, aptamer modification for immobilization or signal generation is ...
-
Manufactured by XyloCor Therapeuticsbased in USA
About the EXACT Trial for Refractory Angina Patients. The EXACT clinical trial is a Phase 1/2 multicenter, open-label, single arm, dose escalation trial. Approximately 12 subjects (N=3 per cohort) who have refractory angina will be enrolled into 4 ascending dose groups, followed by an expansion of the highest tolerated dose with 21 additional subjects. The trial is designed to test the safety and ...
-
Manufactured by RoosterBio, Inc.based in USA
Human Mesenchymal Stem/Stromal Cells (hMSCs) are a heterogeneous cell population derived from a variety of tissue and donor sources. As a raw material in emerging cell, gene, and exosome based therapies, understanding the key quality attributes of your hMSC, such as phenotype, function, and growth kinetics are vital to understanding ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you